6-fluoro-1,2,3,4-tetrahydro-1-methylnaphthalene | 156868-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-fluoro-1,2,3,4-tetrahydro-1-methylnaphthalene
• 英文别名: 6-Fluoro-1-methyl-1,2,3,4-tetrahydronaphthalene
• CAS: 156868-65-4
• 化学式: C₁₁H₁₃F
• 分子量: 164.223
• InChiKey: IJQWBCPVPYZKKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-fluoro-1,2,3,4-tetrahydro-1-methylnaphthalene 在 硝酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-(1-ethylpropyl)-5,6,7,8-tetrahydro-5-methyl-1,3-dinitro-2-naphthalenamine
  参考文献：
  名称：

  Synthesis and Herbicidal Activity of Substituted Tetrahydronaphthalenes (Part II)

  摘要：

  This paper reports the synthesis and the biological activity of novel tetrahydronaphthalenes with substitution of functional groups at each position of the aromatic ring and substitution of various alkyl groups at the 1-position of the non-aromatic ring. These compounds exhibited pre-emergent herbicidal activity which was determined by the orientation and type of functional groups on the aromatic ring with the 1,1-dimethyl substitution on the non-aromatic ring. The activity tended to be highest for nitro or methyl at the 5- and 7-positions with an amino or ester group at the 6-position and a dimethyl substitution at the 1-position.

  DOI：

  10.1002/(sici)1096-9063(199603)46:3<227::aid-ps358>3.0.co;2-v
• 作为产物：
  描述：

  3-氟溴苄 在 吡啶 、 三溴化磷 、 magnesium 、 1,2-二溴乙烷 作用下， 以 苯 为溶剂， 反应 54.25h， 生成 6-fluoro-1,2,3,4-tetrahydro-1-methylnaphthalene
  参考文献：
  名称：

  四氢萘的合成。第二部分

  摘要：

  描述了利用环脱水方法的合成，以制备在芳香环的每个位置上被官能团取代并且在非芳香环的1-位上被多个烷基取代的新型四氢萘。

  DOI：

  10.1016/s0040-4020(01)87011-3

文献信息

• [EN] FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS<br/>[FR] 1,4-OXAZEPINES CONDENSÉES ET LEURS ANALOGUES ASSOCIÉS EN TANT QU'INHIBITEURS DE BROMODOMAINE BET
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017142881A1

  公开（公告）日：2017-08-24

  The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.

  本发明公开了式(I)表示的融合1,4-噁嗪和相关类似物及其药学上可接受的盐、水合物和溶剂化物，其中R1、R2a、R2b、R3a、R3b、R4、R5、A和Y的定义如说明书中所述。本发明还涉及式(I)化合物用于治疗对BET溴结构域抑制有反应的病症或疾病，如癌症的用途。
• [EN] PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE, ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：NANTBIOSCIENCE INC

  公开号：WO2016138527A1

  公开（公告）日：2016-09-01

  The present invention provides kinase inhibitors with anti-proliferative activity comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof. In addition, the invention provides methods for making novel compounds and methods for using the compounds.

  本发明提供了具有抗增殖活性的激酶抑制剂，包括取代嘧啶衍生物及其药用可接受的配方。此外，本发明提供了制备新化合物的方法以及使用这些化合物的方法。
• FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
  申请人：The Regents of The University of Michigan

  公开号：EP3416969B1

  公开（公告）日：2021-05-05
• BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160355521A1

  公开（公告）日：2016-12-08

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
• [EN] AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17<br/>[FR] ANILIDES D'ACIDES AMINÉS EN TANT QUE MODULATEURS À PETITES MOLÉCULES D'IL-17
  申请人：LEO PHARMA AS

  公开号：WO2020127685A1

  公开（公告）日：2020-06-25

  The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.